These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37665421)

  • 1. Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma.
    Zheng Y; Lai Z; Wang B; Wei Z; Zeng Y; Zhuang Q; Liu X; Lin K
    Discov Oncol; 2023 Sep; 14(1):164. PubMed ID: 37665421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
    Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
    Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
    Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
    Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
    Chen L; Liu S; Adah D; Sun Q; Liang Z; Ho M; Sun B
    Immunology; 2023 Jun; 169(2):204-218. PubMed ID: 36640111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer.
    Park JY; Chae JR; Cho YL; Kim Y; Lee D; Lee JK; Kang WJ
    Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33080969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
    Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
    Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of GPC3-CAR-NK cells and optimization as a therapy for HCC.
    Cao B; Ni Q; Chen Z; Yang S; Zhang X; Su H; Zhang Z; Zhao Q; Zhu X; Liu M
    J Leukoc Biol; 2024 Jun; ():. PubMed ID: 38922297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3.
    Arulanandam A; Lin L; Chang HM; Cerutti M; Choblet S; Gao P; Rath A; Bensussan A; Kadouche J; Teper D; Mandelboim O; Li W
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
    Dong Y; Huang Y; Zhang Z; Chen A; Li L; Tian M; Shen J; Shao J
    J Transl Med; 2023 Mar; 21(1):205. PubMed ID: 36932395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Click Chemistry-Mediated Polymannose Surface-Engineering of Natural Killer Cells for Immunotherapy of Triple-Negative Breast Cancer.
    Niu X; Yang H; Guo J; Yao L; Wang Y; Yu W; Liu Z; Chen H
    Adv Healthc Mater; 2024 Jun; ():e2400970. PubMed ID: 38838184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
    Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
    Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
    Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
    J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.
    Jiang W; Zhang C; Tian Z; Zhang J
    Gene Ther; 2013 Nov; 20(11):1062-9. PubMed ID: 23759701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.
    Gong L; Li Y; Cui K; Chen Y; Hong H; Li J; Li D; Yin Y; Wu Z; Huang Z
    Small; 2021 Nov; 17(45):e2103463. PubMed ID: 34761524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redirecting natural killer cells to potentiate adoptive immunotherapy in solid tumors through stabilized Y-type bispecific aptamer.
    Zheng Y; Zhang C; Lai Z; Zeng Y; Li J; Zhang D; Liu X
    Nanoscale; 2021 Jul; 13(25):11279-11288. PubMed ID: 34156057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.